Study: NCT03520686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Pembrolizumab
Description: The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab
Description: The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Description: The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab
Description: The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Description: The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab
Description: The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.